prednisone

P1, N=174, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Apr 2025 --> May 2029 | Trial primary completion date: Dec 2024 --> Aug 2025

The diagnosis of PCL was eventually established. After treatment with methotrexate, followed by external beam radiotherapy, the choroidal infiltrate was normalized on B scan.

P1, N=20, Not yet recruiting, University of Miami

P1/2, N=543, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting

P1/2, N=89, Active, not recruiting, Fondazione Italiana Linfomi - ETS | Trial completion date: Oct 2026 --> Feb 2026

P1/2, N=102, Terminated, Epizyme, Inc. | Active, not recruiting --> Terminated; Sponsor decision, no safety concern

P4, N=30, Not yet recruiting, First Affiliated Hospital of Wenzhou Medical University

While 12-month PFS failed to reach statistical significance, subgroup analyses favor Pola-R-CHP. Further research with a wider population, longer follow-up, and screening of advantageous groups are warranted.

P2, N=23, Active, not recruiting, David Oh | Trial completion date: Oct 2024 --> Aug 2025 | Trial primary completion date: Oct 2024 --> Aug 2025

P3, N=50, Not yet recruiting, Janssen Research & Development, LLC | Initiation date: Feb 2025 --> May 2025

P3, N=1046, Not yet recruiting, Merck Sharp & Dohme LLC

P3, N=696, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: May 2027 --> Nov 2027

P3, N=423, Active, not recruiting, Chipscreen Biosciences, Ltd. | Trial completion date: Mar 2025 --> Jun 2025

P2, N=130, Completed, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Active, not recruiting --> Completed | Trial completion date: May 2025 --> Dec 2024

P3, N=240, Recruiting, Incyte Corporation | Not yet recruiting --> Recruiting

P2, N=26, Active, not recruiting, University of Wisconsin, Madison | Trial completion date: May 2026 --> Feb 2027

P3, N=900, Recruiting, Genmab | Trial primary completion date: Sep 2028 --> Jun 2027

P2, N=67, Completed, Astellas Pharma Global Development, Inc. | Phase classification: P2a --> P2

P3, N=1080, Recruiting, Genmab | Trial completion date: May 2037 --> Nov 2037 | Trial primary completion date: May 2037 --> Nov 2037

P2, N=622, Recruiting, Genmab | Trial completion date: Nov 2032 --> Jun 2031 | Trial primary completion date: Nov 2032 --> Jun 2031

The patient received eight cycles of the CHOP (doxorubicin, cyclophosphamide, prednisone, and vincristine) chemotherapy regimen, achieving complete clinical remission with no recurrence noted at the two-year follow-up. Early recognition is crucial for optimal treatment of this uncommon disease. Further research is needed to refine treatment protocols.

The patient subsequently received four cycles of chemotherapy using rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). After a follow-up of 17 months, the patient is alive with no evidence of disease. This report is being used to discuss the salient features of this rare entity and its differential diagnosis.

P2, N=102, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026

P1, N=352, Recruiting, Ambrx, Inc. | N=262 --> 352 | Trial completion date: Mar 2027 --> Dec 2028 | Trial primary completion date: Dec 2025 --> May 2026

P2, N=20, Recruiting, Tianjin Medical University Cancer Institute and Hospital

P3, N=575, Active, not recruiting, Exelixis | Trial completion date: Aug 2024 --> Oct 2026

P2, N=7, Not yet recruiting, Ruijin Hospital

P2, N=35, Recruiting, Guangzhou JOYO Pharma Co., Ltd

The patient showed a limited response to a combined therapy regimen of prednisone, iguratimod, and tacrolimus. This report also discusses the potential role of inflammatory cytokines in the pathophysiology of CADM and RP-ILD. Further research is required to confirm these results and investigate the application of MMF in maintenance therapy for CADM-associated RP-ILD.

Among men with mCRPC, there was a high burden of CHD, and higher leptin levels were associated with coronary atherosclerosis independently of traditional cardiac risk factors.

Abiraterone combined with prednisone effectively relieves bone pain and improves PSA response rates in CRPC patients, suggesting benefits in enhancing quality of life and reducing testosterone levels without increasing adverse reactions. This therapy appears to have a safety profile comparable to that of conventional treatments.

P=N/A, N=40, Recruiting, University of British Columbia | Not yet recruiting --> Recruiting

Our study demonstrates that our local population has similar clinicopathological and prognostic characteristics of DLBCL as compared to global findings. It also highlights the limitations of R-CHOP(-like) regimens in contemporary DLBCL management and therefore an ongoing need for improved therapeutic strategies.

The patient was treated with six cycles of the R-CHOP regimen (rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone), achieving complete metabolic remission as confirmed by positron emission tomography-computed tomography. Through our literature review of additional six cases of primary seminal vesicle lymphoma, we aim to elucidate the typical clinical presentations, imaging features, pathological characteristics, genetic mutations, and therapeutic strategies, aiming to contribute to better detection and management of this rare malignancy. This case underscores the diagnostic challenges and emphasizes the necessity for heightened clinical suspicion and definitive pathological examination in the management of primary seminal vesicle lymphoma.

It was administered treatment based on prednisone and phototherapy with a good response. This case makes possible an outlook of the demographic data of HMF, and it allows this entity to be taken into consideration for possible differential diagnoses that are not contemplated due to the limited dissemination of knowledge about this disease. It is important to emphasize the knowledge of HMF since early diagnosis and timely treatment will improve the prognosis in our patients and prevent them from being treated incorrectly.

The CHOP regimen induces male reproductive toxicity, potentially mediated through alterations in hormone levels and increased expression of inflammatory cytokines and oxidative stress. Using E2 as the sole predictor in the model accurately predicts the extent of reproductive damage, offering a non-invasive method for detecting reproductive system damage.

Symptoms resolved after treatment with prednisone and therapy interruption of adagrasib followed by a permanent dose reduction. After the dose reduction, there was an ongoing effective tumor response at follow-up, and serum concentrations of adagrasib remained within the therapeutic index. Through this case report, we aim to bring attention to the possibility of this side effect, as we believe it is important to be aware of it for future patients undergoing treatment with adagrasib.

P1/2, N=66, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.

P1, N=28, Completed, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting --> Completed | N=73 --> 28 | Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jul 2024 --> Sep 2024

P1, N=18, Active, not recruiting, Washington University School of Medicine | Trial completion date: Mar 2026 --> Sep 2025

P4, N=130, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University | Phase classification: P1 --> P4

P4, N=58, Completed, The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital of Zhejiang University School of Medicine